Stéphane Champiat, MD, PhD, spoke about the reasoning behind using the IL-2/IL-15 superagonist SOT101 and where the research is heading for patients with solid tumors.
Stéphane Champiat, MD, PhD
Advertisement
Articles by Stéphane Champiat, MD, PhD
Stéphane Champiat, MD, PhD, spoke about the results of the AURELIO-03 trial with SOT101 and pembrolizumab for patients with advanced solid tumors.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer
2
Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL
3
How Can Oncology Staffing Shortages Be Remedied?
4
Lifileucel Confers Durable Responses in Pretreated Advanced NSCLC Type
5
